Draft guideline on core summary of product characteristics for human fibrinogen products

  • Email
  • Help

Document details

Download document Draft guideline on core summary of product characteristics for human fibrinogen products
Reference number EMA/CHMP/BPWP/691754/2013 Rev. 1
Status draft: consultation closed
First published 2014-03-04
Last updated 2014-03-04

Summary

This guideline describes the information to be included in the summary of product characteristics for human fibrinogen, which is indicated for the treatment and prophylaxis of bleeding in patients with congenital hypo-, dys- or afibrinogenaemia with bleeding tendency and as a complementary therapy to management of uncontrolled severe haemorrhage in acquired hypofibrinogenaemia.